Critical assessment of a prolonged-release EE/DNG contraceptive safety analysis

The European Journal of Contraception & Reproductive Health Care 2026

View at publisher
Authors: Jonathan Douxfils, Nathalie Chabbert‐Buffet, Mitchell David Creinin, Marie Didembourg, Jean‐Michel Dogné, Jean-Michel Foidart, ULYSSE J. GASPARD, Oskari Heikinheimo, Øjvind Lidegaard, Médéa Locquet, Laure Morimont, Lucie Raskin
+2 more Kristina Gemzell‐Danielsson, Helena Kopp Kallner
DOI: 10.1080/13625187.2026.2627482
Cited by: 0
References: 4

Abstract

Dear EditorThe recently published rapid communication by Grandi et al. [1] on the “one-year clinical experience” with the prolonged-release ethinylestradiol (EE) 0.02 mg/dienogest (DNG) 2 mg combin...

Fields of Study & Subjects

Reproductive Health and Contraception Pharmacovigilance and Adverse Drug Reactions International Human Rights and Reproductive Law

Publication details

Journal / source
The European Journal of Contraception & Reproductive Health Care
Volume
31
Issue
3
Pages
197–200
Publication date
17 February 2026
Language
EN